1
On June 18, 2024, Day One Biopharmaceuticals, a company listed on the United States NASDAQ, announced that it had entered into an exclusive license agreement with MabCare Therapeutics from Shanghai, China, and Day One will have the exclusive global rights to develop, manufacture and commercialize MTX-13 outside of Greater China.www.pharnexcloud.com
Under the terms of the agreement, MabCare Therapeutics received an upfront payment of US$55 million (approximately RMB 399 million) and is eligible for additional milestone payments of up to US$1.152 billion for development, regulatory registration and commercialization, as well as low-single-digit royalties on net sales outside of Greater China.
pipeline
MTX-13 (DAY301) is a novel ADC targeting protein tyrosine kinase 7 (PTK7). In April 2024, the United States FDA approved an IND application for the initiation of clinical trials of MTX-13.
Day One expects to conduct the first clinical trial as soon as the fourth quarter of 2024. The MTX-13 was previously developed by MabCare in collaboration with companies such as Puzhong Discovery.
Schematic diagram of PTK7 ADC structure
Yaorong Cloud Data www.pharnexcloud.com; entry
2
In July 2024, Zai Lab entered into a strategic collaboration and global licensing agreement with Maxbios. Through this collaboration, Zai Lab has acquired the ROR1 ADC ZL-6301 based on a next-generation platform, further expanding the company's global oncology pipeline. ROR1 is widely expressed in solid tumors and hematologic tumors, and has been preliminarily validated in hematologic tumors. ZL-6301 is expected to have a breakthrough in solid tumors. ZL-6301 has demonstrated encouraging preclinical performance and is currently in the clinical study preparation stage. Zai Lab plans to work to advance its global clinical development.
http://ir.zailaboratory.com
3
Maxbio is a start-up drug company from China, which was first established on August 16, 2022. In addition, another HER3-targeting ADC drug, AMT-562, was also co-developed (with Discovery and others). The founder of the company is Dr. Meng Tao, who graduated from the School of Pharmacy of Fudan University in 2000 with a bachelor's degree. In the same year, he joined the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and graduated with a Ph.D. degree in medicinal chemistry in 2007. From 2008 to 2009, he was funded by Actelion in Switzerland to carry out postdoctoral research at Bern University in Switzerland, and was promoted to researcher in September 2015, and then started biotech. Introduction at the Institute of Materia Medica: The research work is mainly focused on medicinal chemistry and the research of new antibody drug conjugates. So far, he has published 27 articles and 14 patents. Among them, the mTOR inhibitor patent as the core inventor has completed the transformation of the results, and obtained clinical approval as the first mTOR inhibitor in China. The research work has been supported by the "Eleventh Five-Year Plan" and "Twelfth Five-Year Plan" major new drug projects and the National Natural Science Foundation of China.
Reference:
NMPA/CDE；
Yaorong Cloud Data www.pharnexcloud.com;
FDA/EMA/PMDA;
public disclosure by the relevant company;
https://www.dayonebio.com/；
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers；
https://ir.dayonebio.com/events-and-presentations；
http://sourcedb.simm.cas.cn/zw/ds/201605/t20160512_4600993.html；
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Company Progress, https://mp.weixin.qq.com/s/RHcD1lm0OB1HeDha0la0Sw;
Wait a minute.
This article is only intended to provide scientific information to medical and health professionals, and does not represent the position of the platform and does not make any medication recommendations